Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia

Cerebellum. 2022 Feb;21(1):39-47. doi: 10.1007/s12311-021-01257-4. Epub 2021 Apr 24.

Abstract

Ataxia telangiectasia (A-T) is a progressive and life-limiting disease associated with cerebellar ataxia due to progressive cerebellar degeneration. In addition to ataxia, which is described in detail, the presence of chorea, dystonia, oculomotor apraxia, athetosis, parkinsonism, and myoclonia are typical manifestations of the disease. The study aimed to evaluate the specificity and sensitivity of neurofilament light chain (NfL) as a biomarker of neurodegeneration in relation to SARA score. In this prospective trial, one visit of 42 A-T patients aged 1.3-25.6 years (mean 11.6 ± 7.3 years) was performed, in which NfL was determined from serum by ELISA. Additionally, a neurological examination of the patients was performed. Blood was collected from 19 healthy volunteers ≥ 12 years of age. We found significantly increased levels of NfL in patients with A-T compared to healthy controls (21.5 ± 3.6 pg/mL vs. 9.3 ± 0.49 pg/mL, p ≤ 0.01). There was a significant correlation of NfL with age, AFP, and SARA. NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.

Keywords: Ataxia telangiectasia; Biomarker; Disease progression; Neurodegeneration; Neurofilament light chain; NfL.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Ataxia Telangiectasia* / diagnosis
  • Biomarkers
  • Cerebellar Ataxia*
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Intermediate Filaments
  • Neurofilament Proteins
  • Prospective Studies
  • Young Adult

Substances

  • Biomarkers
  • Neurofilament Proteins